COVID-19 INFORMATION What you need to know about the coronavirus if you are living in Japan or planning a visit.

U.S. drugmaker reports promising early results from COVID-19 vaccine test

By Ivan Couronne

The requested article has expired, and is no longer available. Any related articles, and user comments are shown below.

© 2020 AFP

©2020 GPlusMedia Inc.

Login to comment

Be interesting to see their SEC filings from just before they made the announcement. The US stockmarket has been more nervous than a long-tailed cat in a room full of rocking chairs lately, responding mostly to innuendo and rumor..

0 ( +0 / -0 )

Good news. They will be heroes if this works.

0 ( +0 / -0 )

All cures pedalled by usa should have all all the trump administration and moderna company top to bottom employees taking them first. This is either a case prepared long ago or some bad joke.

0 ( +2 / -2 )

Saw an interview of a vaccine trial volunteer on local TV news yesterday. He's part of an Emory University study. The side effect he mentioned was waking up with a stiff neck, but he didn't know whether that was caused by the 2 doses or just because he slept wrong. That study has been approved for Phase 2 trials. No other details about the trial or the participant's qualifications were provided - typical non-technical reporter stuff more interested in asking about "feelings" than facts. Hopefully, they got volunteers who were/are caring for family members with confirmed COVID-19. I hope Ars Technica has an article about these trials soon. They are a science/technology online site that takes the time to create accurate, longer-form, articles by teams with a background in the subject matter.

The phase 1 trials were very limited, 6-10 people.

Once the DNA was published to the world, computers everywhere started trying to simulate vaccines to make the virus impotent. A number of different possible solutions were found that way which moved on to lab studies. The TV New "magazine" 60 Minutes did an episode about this a few weeks ago.

While I'm hopeful, I won't be getting the vaccine until after millions and millions of other humans have taken it. I love proven safe vaccines. Get all the boosters and recommended ones pre-travel based on the dangers of the location. But I'd rather not be a guinea pig. We can stay home the rest of the year, if needed.

0 ( +0 / -0 )


A year after it attracted the largest private financing round ever for a biotechnology company, Moderna Therapuetics is receiving another major show of support for its messenger RNA (mRNA) technology. The Bill & Melinda Gates Foundation has announced a $20-million grant to Moderna to advance the development of an affordable mRNA-based cocktail of antibody therapeutics to help prevent human immunodeficiency virus (HIV) infection.

what a coincidence. and it was 2016...

-1 ( +0 / -1 )

It's important to note that the theoretical process of creating a human vaccine using mRNA has never been proven or accomplished.

Sars-cov-2 is an RNA virus. RNA viruses mutate very quickly, meaning that if a vaccine is ever developed, the virus will have likely mutated and the vaccine will be ineffective against the new mutated one. So, you have to start all over again and may end up with several vaccines to cover multiple mutations.

Flu vaccines are like this. That's why they are generally only 50% or less effective, because we can't guess which variations will be prevalent after the vaccine cocktail is manufactured.

0 ( +0 / -0 )

Sars-cov-2 is an RNA virus. RNA viruses mutate very quickly, meaning that if a vaccine is ever developed, the virus will have likely mutated and the vaccine will be ineffective against the new mutated one.

No, that is not correct, there are plenty of vaccines against RNA viruses because mutation do not automatically means antibodies stop being effective. Japanese encephalitis virus or Yellow fever virus mutate incredibly fast and dozens and dozens of variants can be found from samples from a single patient, but vaccines for both have been perfectly safe and efficient for decades without needing multiple variants.

Influenza is an special case, and efficacy changes every year, we can't guess perfectly, but some years it is a very nice match.

0 ( +0 / -0 )

Login to leave a comment

Facebook users

Use your Facebook account to login or register with JapanToday. By doing so, you will also receive an email inviting you to receive our news alerts.

Facebook Connect

Login with your JapanToday account

User registration

Articles, Offers & Useful Resources

A mix of what's trending on our other sites